Similarly, trastuzumab plus LIFU increased median survival and reduced tumor volume as compared to non-treated group in a Her2 and neu positive model of brain metastasis of breast cancer.84 Despite evidence of preclinical success, LIFU parameters such as including power, cavitation dose, and duration of sonication needs to be elucidated to achieve consistent and reliable BBB/BTB opening in clinical studies. The gene discussed is ERBB2; the disease is breast carcinoma.